Scopus Asset Management’s Colgate-Palmolive CL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-537,500
Closed -$38.2M 243
2023
Q3
$38.2M Buy
537,500
+132,500
+33% +$9.91M 1.09% 26
2023
Q2
$31.2M Buy
+405,000
New +$31.3M 0.87% 39
2023
Q1
Sell
-887,500
Closed -$69.9M 229
2022
Q4
$69.9M Buy
887,500
+237,500
+37% +$17.8M 1.9% 4
2022
Q3
$45.7M Buy
650,000
+50,000
+8% +$3.92M 1.69% 8
2022
Q2
$48.1M Buy
+600,000
New +$46.9M 2.65% 5
2021
Q3
Sell
-700,000
Closed -$56.9M 367
2021
Q2
$56.9M Buy
+700,000
New +$57.2M 0.74% 34
2021
Q1
Sell
-650,000
Closed -$55.6M 380
2020
Q4
$55.6M Buy
+650,000
New +$53.7M 0.89% 21
2017
Q2
Sell
-350,000
Closed -$25.6M 254
2017
Q1
$25.6M Buy
+350,000
New +$24.5M 0.39% 88

Other funds holding CL

Scopus Asset Management's CL Position: Q4 2023 in Review

Scopus Asset Management sold out of Colgate-Palmolive (CL) in Q4 2023, closing a stake of 537,500 shares — an estimated $38.2M sold.

Scopus Asset Management first reported a position in CL in Q1 2017 and held it in 8 quarters. The position peaked at $69.9M in Q4 2022. 1,741 funds tracked by Wall St. Rank hold CL as of Q4 2023.

  • Scopus Asset Management reported no remaining Colgate-Palmolive position as of Q4 2023 after selling out during the quarter.
  • Scopus Asset Management sold 537,500 Colgate-Palmolive shares in Q4 2023, an estimated $38.2M.
  • Scopus Asset Management first reported a position in Colgate-Palmolive in Q1 2017 and held it in 8 quarters.
  • Scopus Asset Management's Colgate-Palmolive position peaked at $69.9M in Q4 2022.
  • 1,741 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q4 2023.

Based on Scopus Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.